# Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

> **NCT03209869** · PHASE1 · WITHDRAWN · sponsor: **University of Wisconsin, Madison**

## Conditions studied

- Neuroblastoma
- Relapsed Neuroblastoma
- Recurrent Neuroblastoma
- Osteosarcoma

## Interventions

- **BIOLOGICAL:** Ex vivo Expanded and Activated Haploidentical Donor NK Cells
- **BIOLOGICAL:** Hu14.18-IL2

## Key facts

- **NCT ID:** NCT03209869
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-12
- **Primary completion:** 2022-09-07
- **Final completion:** 2022-09-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** resources limited due to COVID-19
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03209869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03209869, "Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03209869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*